Typhoid fever

  • Christopher M. Parry
Article

Abstract

Typhoid fever is caused by infection with Salmonella enterica serovar Typhi. The completion of the genome sequence of two Salmonella enterica serovar Typhi isolates is leading to new insights into the biology of this pathogen. Approximately 16 million cases occur worldwide each year. The lack of culture facilities in endemic areas and the poor performance of the Widal test means the disease is frequently unconfirmed. Simple new serologic tests are being developed and show promise. Resistance to chloramphenicol, ampicillin, and trimethoprim/sulfamethoxazole is widespread in Asia and some areas of Africa, although fully susceptible isolates have re-emerged in some countries. Fluoroquinolones, third-generation cephalosporins, and azithromycin are effective alternatives. Low-level fluoroquinolone resistance (indicated by resistance to nalidixic acid) is now common in Asia and results in a suboptimal response to fluoroquinolones. Two vaccines are licensed and others are being developed, but neither licensed vaccine is used in endemic areas as a public health measure.

References and Recommended Reading

  1. 1.
    Parry CM, Hien TT, Dougan G, et al.: Typhoid Fever. N Engl J Med 2002, 347:1770–1782.PubMedCrossRefGoogle Scholar
  2. 2.
    Kidgell C, Reichard U, Wain J, et al.: Salmonella typhi, the causative agent of typhoid fever, is approximately 50,000 years old. Infect Genet Evol 2002, 2:39–45.PubMedCrossRefGoogle Scholar
  3. 3.
    Parkhill J, Dougan G, James KD, et al.: Complete genome sequence of a multiple drug resistant Salmonella enterica serovar Typhi CT18. Nature 2001, 413:848–852.PubMedCrossRefGoogle Scholar
  4. 4.
    Deng W, Liou SR, Plunkett III G, et al.: Comparative genomics of Salmonella enterica serovar Typhi strains Ty2 and CT18. J Bacteriol 2003, 185:2330–2337. The authors of this study completed the genome sequence of S. Typhi Ty2. S. Typhi Ty2 is the foundation for vaccine development and the parent of mutant strains TY21a and CVD908 and their derivatives. When compared with the genome of S. Typhi CT18, there were genes unique to each strain and additional differences in prophages, insertion sequences, and island structures.PubMedCrossRefGoogle Scholar
  5. 5.
    McClelland M, Sanderson KE, Spieth J, et al.: The complete genome sequence of Salmonella enterica serovar Typhimurium LT2. Nature 2001, 413:852–856.PubMedCrossRefGoogle Scholar
  6. 6.
    Porwollik S, McClelland M: Lateral gene transfer in Salmonella. Microbes Infect 2003, 5:977–989.PubMedCrossRefGoogle Scholar
  7. 7.
    Boyd EF, Porwollik S, Blackmer F, McClelland M: Differences in gene content among Salmonella enterica serovar Typhi isolates. J Clin Microbiol 2003, 41:3823–3828. This study, using DNA microarray technology, shows that although S. Typhi is a highly clonal bacterium, there are significant interstrain variations in the genome content.PubMedCrossRefGoogle Scholar
  8. 8.
    Chan K, Baker S, Kim CC, et al.: Genomic comparison of Salmonella enterica serovars and Salmonella bongori by use of an S. enterica serovar typhimurium DNA microarray. J Bacteriol 2003, 185:553–563. This study, using DNA microarray technology, shows that although S. Typhi is a highly clonal bacterium, there are significant interstrain variations in the genome content.PubMedCrossRefGoogle Scholar
  9. 9.
    Pickard D, Wain J, Baker S, et al.: Composition, acquisition, and distribution of the Vi exoplysaccharide-encoding Salmonella enterica pathogenicity island SPI-7. J Bacteriol 2003, 185:5055–5065.PubMedCrossRefGoogle Scholar
  10. 10.
    Thong KL, Goh YL, Yasin RM, et al.: Increasing genetic diversity of Salmonella enterica serovar Typhi isolates from Papua New Guinea over the period from 1992 to 1999. J Clin Microbiol 2002, 40:4156–4160. Using PFGE and phage typing, this study clearly indicates that infection with S. Typhi may occur with multiple strains.PubMedCrossRefGoogle Scholar
  11. 11.
    Liu Y, Lee MA, Ooi EE, et al.: Molecular typing of Salmonella enterica serovar Typhi isolates from various countries in Asia by a multiplex PCR assay on variable-number tandem repeats. J Clin Microbiol 2003, 41:4388–4394.PubMedCrossRefGoogle Scholar
  12. 12.
    Bhan MK, Bahl R, Sazawal S, et al.: Association between Helicobacter pylori infection and increased risk of typhoid fever. J Infect Dis 2002, 186:1857–1860. In a nested case-control study in an urban slum in Dehli, India, the presence of serum immunoglobulin G antibodies against H. pylori is associated with an increased risk for typhoid fever.PubMedCrossRefGoogle Scholar
  13. 13.
    Crump JA, Youssef FG, Luby SP, et al.: Estimating the incidence of typhoid fever and other febrile illnesses in developing countries. Emerg Infect Dis 2003, 9:539–544.PubMedGoogle Scholar
  14. 14.
    Chandel DS, Chaudhry R, Dhawan B, et al.: Drug-resistant Salmonella enterica serotype Paratyphi A in India. Emerg Infect Dis 2000, 6:420–421.PubMedCrossRefGoogle Scholar
  15. 15.
    Tankhiwale SS, Agrawal G, Jalgaonkar SV: An unusually high occurrence of Salmonella enterica serotype Paratyphi A in patients with enteric fever. Indian J Med Res 2003, 117:10–12.PubMedGoogle Scholar
  16. 16.
    Rodrigues C, Shennai S, Mehta A: Enteric fever in Mumbai, India: the good news and the bad news. Clin Infect Dis 2003, 36:535.PubMedCrossRefGoogle Scholar
  17. 17.
    Ackers ML, Puhr ND, Tauxe RV, Mintz ED: Laboratory-based surveillance of Salmonella serotype Typhi infections in the United States. JAMA 2000, 283:2668–2673.PubMedCrossRefGoogle Scholar
  18. 18.
    Olsen SJ, Bleasdale SC, Magnano AR, et al.: Outbreaks of typhoid fever in the United States, 1969–99. Epidemiol Infect 2003, 130:13–21.PubMedCrossRefGoogle Scholar
  19. 19.
    Reller ME, Olsen SJ, Kressel AB, et al.: Sexual transmission of typhoid fever: a multistate outbreak among men who have sex with men. Clin Infect Dis 2003, 37:141–144.PubMedCrossRefGoogle Scholar
  20. 20.
    Hatta M, Mubin H, Abdoel T, Smits H: Antibody response in typhoid fever in endemic Indonesia and the relevance of serology and culture to diagnosis. Southeast Asian J Trop Med Hyg 2002, 33:742–751. In this study, the authors evaluate a rapid, dipstick serologic test for typhoid in 473 patients with suspected typhoid. The sensitivity when a single sample was tested was 58%, and specificity was 98%. The sensitivity increased with duration of illness, and many of the dipsticknegative patients with typhoid became positive later in the illness.Google Scholar
  21. 21.
    Ismail TF, Smits H, Wafsy MO, et al.: Evaluation of dipstick serological tests for diagnosis of brucellosis and typhoid fever in Egypt. J Clin Microbiol 2002, 40:3509–3511.PubMedCrossRefGoogle Scholar
  22. 22.
    Khan E, Azam I, Ahmed S, Hassan R: Diagnosis of typhoid fever by dot enzyme immunoassay in an endemic region. J Pak Med Assoc 2002, 52:415–417.PubMedGoogle Scholar
  23. 23.
    Herath HM: Early diagnosis of typhoid fever by the detection of salivary IgA. J Clin Pathol 2003, 56:694–698.PubMedCrossRefGoogle Scholar
  24. 24.
    Kumar A, Arora V, Bashaboo A, Ali S: Detection of Salmonella typhi by polymerase chain reaction: implications in diagnosis of typhoid fever. Infect Genet Evol 2002, 2:107–110.PubMedCrossRefGoogle Scholar
  25. 25.
    Shwe TN, Nyein MM, Yi W, Mon A: Blood culture isolates from children admitted to Medical Unit III, Yangon Children’s Hospital, 1998. Southeast Asian J Trop Med Hyg 2002, 33:764–771.Google Scholar
  26. 26.
    Saha MR, Dutta P, Niyogi SK, et al.: Decreasing trend in the occurrence of Salmonella enterica serotype Typhi amongst hospitalised children in Kolkata, India during 1990–2000. Indian J Med Res 2002, 115:46–48.PubMedGoogle Scholar
  27. 27.
    Wafsy MO, Frenck R, Ismail TF, et al.: Trends of multiple-drug resistance among Salmonella serotype Typhi isolates during a 14-year period in Egypt. Clin Infect Dis 2002, 35:1265–1268.CrossRefGoogle Scholar
  28. 28.
    Mills-Robertson F, Addy ME, Mensah P, Crupper SS: Molecular characterization of antibiotic resistance in clinical Salmonella typhi isolated in Ghana. FEMS Microbiol Lett 2002, 215:249–253.PubMedCrossRefGoogle Scholar
  29. 29.
    Dromgny A, Perrier-Gros-Claude JD: Antimicrobial resistance of Salmonella enterica serotype Typhi in Dakar, Senegal. Clin Infect Dis 2003, 37:465–466.CrossRefGoogle Scholar
  30. 30.
    Wain J, Diem Nga LT, Kidgell C, et al.: Molecular analysis of incHI1 antimicrobial resistance plasmids from Salmonella serovar Typhi strains associated with typhoid fever. Antimicrob Agents Chemother 2003, 47:2732–2739. A core region of the antimicrobial resistance plasmid of S. Typhi CT18 shows significant DNA sequence similarity to R27, a plasmid isolated from a Salmonella in 1961. This R27-like plasmid has evolved by the serial acquisition of DNA on mobile elements encoding resistance to antimicrobials, heavy metals, and genes of unknown function, and has spread into several S. Typhi genotypes across southern Vietnam.PubMedCrossRefGoogle Scholar
  31. 31.
    Pai H, Byeon JH, Yu S, et al.: Salmonella enterica serovar Typhi strains isolated in Korea containing a multidrug resistance class 1 integron. Antimicrob Agents Chemother 2003, 47:2006–2008.PubMedCrossRefGoogle Scholar
  32. 32.
    Ploy MC, Chainier D, Tran Thi NH, et al.: Integron-associated antibiotic resistance in Salmonella enterica serovar Typhi from Asia. Antimicrob Agents Chemother 2003, 47:1427–1429.PubMedCrossRefGoogle Scholar
  33. 33.
    Tran HJ, Jacoby GA: Mechanism of plasmid-mediated quinolone resistance. Proc Natl Acad Sci USA 2002, 99:5638–5642.PubMedCrossRefGoogle Scholar
  34. 34.
    Asna SM, Haq JA, Rahman MM: Nalidixic acid-resistant Salmonella enterica serovar Typhi with decreased susceptibility to ciprofloxacin caused treatment failure: a report from Bangladesh. Jpn J Infect Dis 2003, 56:32–33.PubMedGoogle Scholar
  35. 35.
    Aerustrup FM, Wiuff C, Mølbak K, Threlfall EJ: Is it time to change the fluoroquinolone breakpoints for Salmonella spp.? Antimicrob Agents Chemother 2003, 47:827–829. This paper addresses the important issue of low-level fluoroquinolone resistance in S. Typhi and non-Typhi Salmonella. It highlights the suboptimal outcome when fluoroquinolones are used to treat infections with such strains and outlines measures to improve their laboratory detection.CrossRefGoogle Scholar
  36. 36.
    Crump JA, Barrett TJ, Nelson JT, Angulo FJ: Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-Typhi Salmonellae. Clin Infect Dis 2003, 37:75–81. This paper addresses the important issue of low-level fluoroquinolone resistance in S. Typhi and non-Typhi Salmonella. It highlights the suboptimal outcome when fluoroquinolones are used to treat infections with such strains and outlines measures to improve their laboratory detection.PubMedCrossRefGoogle Scholar
  37. 37.
    National Committee for Clinical Laboratory Standards (NCCLS): Performance standards for antimicrobial susceptibility testing: 13th informational supplement. Wayne, PA: NCCLS; 2003:NCCLS document M100-S13 (M7).Google Scholar
  38. 38.
    Stephens I, Levine MM: Management of typhoid fever in children. Pediatr Infect Dis J 2002, 21:157–159.PubMedCrossRefGoogle Scholar
  39. 39.
    Lee CL, Duffy C, Gerbino PG, et al.: Tendon and joint disorders in children after treatment with fluoroquinolones or azithromycin. Pediatr Infect Dis J 2002, 21:525–529. This retrospective observational study of more than 6000 children treated with fluoroquinolones concludes that the incidence of tendon and joint disorders associated with fluoroquinolone use is less than 1% and comparable with the incidence in a reference group of children treated with azithromycin.CrossRefGoogle Scholar
  40. 40.
    Gasem MH, Keuter M, Dolmans WM, et al.: Persistence of Salmonellae in blood and bone marrow: randomized controlled trial comparing ciprofloxacin and chloramphenicol treatments against enteric fever. Antimicrob Agents Chemother 2003, 47:1727–1731.PubMedCrossRefGoogle Scholar
  41. 41.
    Tatli MM, Aktas G, Kossecik M, Yilmaz A: Treatment of typhoid fever in children with a flexible duration of ceftriaxone, compared with 14-day treatment with chloramphenicol. Int J Antimicrob Agents 2003, 21:350–353.PubMedCrossRefGoogle Scholar
  42. 42.
    Önen A, Dokucu AI, Çigdem MK, et al.: Factors effecting morbidity in typhoid intestinal perforation in children. Pediatr Surg Int 2002, 18:696–700. The authors of this retrospective review of 42 children with typhoid perforation suggest that children with severe peritonitis and a long delay between perforation and operation have a lower complication rate if the operative treatment includes an ileostomy and if they receive postoperative parenteral nutrition.PubMedGoogle Scholar
  43. 43.
    Agbakwuru EA, Adesunkanmi AR, Fadiora SO, et al.: A review of typhoid perforation in a rural African Hospital. West Afr J Med 2003, 22:22–25.PubMedGoogle Scholar
  44. 44.
    Garmory HS, Brown KA, Titball RW: Salmonella vaccines for use in humans: present and future perspectives. FEMS Microbiol Rev 2002, 26:339–353.PubMedGoogle Scholar
  45. 45.
    Lin FY, Vo VA, Khiem HB, et al.: The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001, 344:1263–1269.PubMedCrossRefGoogle Scholar
  46. 46.
    Lanh MN, Bay PV, Ho VA et al.: Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. N Engl J Med 2003, 349:1390–1391.CrossRefGoogle Scholar
  47. 47.
    Bodhidatta L, Taylor DN, Thisyakorn U, Echeverria P: Control of typhoid fever in Bangkok, Thailand, by annual immunization of school children with parenteral typhoid vaccine. Rev Infect Dis 1987, 9:841–845.PubMedGoogle Scholar
  48. 48.
    Tarr PE, Kuppens L, Jones TC, et al.: Considerations regarding mass vaccination against typhoid fever as an adjunct to sanitation and public health measures: potential use in an epidemic in Tajikistan. Am J Trop Med Hyg 1999, 61:163–170.PubMedGoogle Scholar
  49. 49.
    Taylor DN, Levine MM, Kuppens L, Ivanoff B: Why are typhoid vaccines not recommended for epidemic typhoid fever? J Infect Dis 1999, 180:2089–2090.PubMedCrossRefGoogle Scholar
  50. 50.
    WHO background document. The diagnosis, treatment and prevention of typhoid fever. WHO/V&B/03.07. http:// www.who.int/vaccines-documents/DocsPDF03/www740.pdf. Accessed October 24, 2003. This is a World Health Organization background document compiled by an international group of physicians and scientists that summarizes the current issues regarding the diagnosis, treatment, and prevention of typhoid fever.Google Scholar

Copyright information

© Current Science Inc. 2004

Authors and Affiliations

  • Christopher M. Parry
    • 1
  1. 1.University Department of Medical Microbiology and Genitourinary Medicine, Duncan BuildingRoyal Liverpool University HospitalLiverpoolUK

Personalised recommendations